

Pathogenesis of Type 2 Diabetes

Genetic susceptibility, environmental exposures, and metabolic failure

Dr Abu Suraih Sakhri


MBBS, MD (Pathology)

www.abusuraihsakhri.com

Learning objectives

- Explain why genetic susceptibility alone does not determine disease expression.
- Trace obesity-related insulin resistance to impaired glucose homeostasis.
- Describe the transition from β -cell compensation to relative insulin deficiency.
- Integrate inflammation, lipid excess, and clinical phenotypes into one causal model.

Type 2 diabetes is a multifactorial disorder



The pathways interact and do not imply one obligatory sequence for all patients.

Hyperglycemia requires interacting defects

Insulin resistance

Target tissues respond inadequately to insulin; Demand for insulin rises.

β -cell dysfunction

Insulin secretion becomes insufficient for the prevailing resistance and glucose burden.

Resistance commonly appears first; Failure of compensation allows persistent hyperglycemia.

Type 2 differs fundamentally from type 1 diabetes

Type 1 diabetes

- Islet-directed autoimmune injury
- Progressive loss of insulin-producing β -cells
- Autoantibodies may identify presymptomatic disease

Type 2 diabetes

- No established autoimmune basis in this account
- Insulin resistance and inadequate β -cell compensation
- Genetic, metabolic and inflammatory mechanisms

Proinflammatory mechanisms in T2D do not make it an autoimmune disease.

Three interacting causal domains

Inherited predisposition

Polygenic variants affect adiposity and β -cell function.

Acquired exposures

Central adiposity, inactivity and circadian disruption.

Metabolic inflammation

Lipid excess and cytokines weaken insulin action and islet function.

None is a complete explanation in isolation.

Familial aggregation indicates inherited susceptibility

5–10×

Higher risk in first-degree relatives (age- and weight-matched)

The textbook uses familial clustering as evidence for genetic contribution, not proof of a single-gene cause.


Twin concordance supports a strong genetic component

>90%

Reported concordance in monozygotic twins

Concordance is not the same as genetic determinism;
Shared environments can contribute.

Type 2 diabetes usually has a polygenic basis



Common variants act together rather than following a simple Mendelian pattern.

Genome-wide association studies identify risk loci

≥ 30

Loci reported in the source text

Many associated loci with individually minimal to modest lifetime-risk contributions; This is an edition-specific statement, not a current locus census.

Risk loci implicate several biological systems

Adipose tissue

Body-fat distribution and metabolic behavior.

Pancreatic islets


β -cell function and insulin secretion.

Energy balance

Obesity susceptibility.


Genetic associations converge on mechanisms rather than one universal defect.

Fat distribution is partly genetically influenced



Inherited variation can influence where excess adipose tissue is deposited.

β -cell biology is an inherited vulnerability



Many risk polymorphisms affect insulin secretion, not simply body weight.

A family history is a risk indicator—not a diagnosis

What family history supports

- Higher prior probability of T2D
- Shared genetic and environmental liability
- Attention to modifiable exposures

What it does not establish

- A single causative mutation
- Current insulin resistance or hyperglycemia
- Inevitable future diabetes

Separate predisposition from the phenotype.

Genetic predisposition meets the environment

Two causal dimensions

Susceptibility	Inherited propensity to adiposity or β -cell stress
Exposure	Adiposity, inactivity, sleep/circadian disruption
Expression	Insulin resistance with inadequate compensation

A conceptual interaction model; No numerical risk estimates are implied.

Central obesity is the major acquired risk factor

Visceral fat

More closely associated with insulin resistance than peripheral adiposity

Obesity—particularly central or visceral obesity—is the leading acquired T2D risk factor described here.

Fat distribution matters beyond body mass index

Visceral/central adiposity

- Greater lipolytic activity
- Higher free fatty acid flux
- Stronger association with insulin resistance

Predominantly subcutaneous adiposity


- Different depot physiology
- May confer comparatively lower metabolic risk
- BMI alone cannot identify this pattern

The two fat compartments are not interchangeable.

Body mass index is an imperfect metabolic proxy


- Body mass index approximates overall adiposity, not its location.
- Central adipose accumulation can carry risk not reflected by BMI alone.
- The source describes individuals with T2D despite lacking overt generalized obesity.
- Risk assessment must consider fat distribution and metabolic context.

Metabolically important adiposity may be concealed



This phenotype in some Asian and Middle Eastern populations.

Weight loss can improve insulin action



The source reports benefit even with modest weight reduction; No specific threshold is provided.

Physical inactivity acts independently of obesity

Low physical activity


- Independent acquired T2D risk factor
- Lower insulin responsiveness can occur without obesity
- Contributes to metabolic vulnerability

Exercise

- Improves insulin sensitivity
- Promotes GLUT4 translocation in muscle
- Complements weight reduction

Exercise is not simply a weight-loss intervention.

Exercise alters muscle glucose transport



This is one exercise-related mechanism.

Weight loss and exercise have additive benefits

Weight reduction

Improves resistance related to excess adiposity.

Physical activity

Improves muscular glucose handling.

Combined approach

May yield additive gains in insulin sensitivity.

This mechanistic complementarity underlies early lifestyle intervention.

Metabolic syndrome clusters related abnormalities

Central obesity

Visceral adipose burden

Hyperglycemia

Disordered glucose homeostasis

Dyslipidemia

Elevated cholesterol / triglycerides

Hypertension

Associated vascular risk

The source groups these features under metabolic syndrome; Diagnostic thresholds are not specified here.

Sleep and circadian disruption contribute to risk

Sleep disorders

Obstructive sleep apnea is an example.

Shift work


Behavioral schedule can conflict with endogenous timing.

Restricted sleep

Nighttime sleep and daytime wakefulness become misaligned.


These are additional risks beyond adiposity and inactivity.

Circadian misalignment perturbs glucose regulation




Robbins also reports genetic associations involving circadian-regulated genes.

Acquired risks converge on common physiology




Circadian disruption can also interfere directly with insulin secretion.

Insulin resistance often appears before diabetes




A conceptual sequence, not a measured time scale.

Early β -cell compensation preserves euglycemia



Hyperinsulinemia can coexist with normal glucose tolerance early on.

Relative insulin deficiency drives progression



“Relative deficiency” means too little insulin for the metabolic need—not necessarily absent insulin.

Insulin resistance affects three major tissues

Liver

Failure to suppress glucose output.

Skeletal muscle


Reduced postprandial glucose disposal.

Adipose tissue

Failure to suppress lipolysis.


These abnormalities explain different aspects of glucose dysregulation.

Hepatic resistance elevates fasting glucose




Insulin normally suppresses hepatic glucose production.

Muscle resistance elevates post-meal glucose



Skeletal muscle is a major insulin-responsive site for glucose uptake.

Adipose resistance releases excess fatty acids



Insulin resistance in fat can amplify resistance elsewhere.

Insulin signaling can fail before glucose transport



A functional signaling defect; Not necessarily a mutation of the insulin receptor.

GLUT4 connects signaling to muscle uptake

Effective insulin action


- Receptor/IRS signaling proceeds
- GLUT4 increases at plasma membrane
- Muscle glucose uptake increases

Insulin resistance

- Receptor/IRS signaling is attenuated
- Surface GLUT4 is reduced
- Muscle glucose uptake is diminished


GLUT4 is a transporter response, not an insulin receptor.

Visceral fat increases free-fatty-acid exposure



The textbook links central fat distribution to excess FFA supply.

Intracellular lipid intermediates disrupt signaling



This is the lipotoxic signaling framework; Diagrams are conceptual.

Fatty acids influence glucose use by two routes

Direct tissue effect


- Lipid intermediates impair insulin signaling
- Reduced insulin-stimulated glucose uptake
- Competition between fuels for oxidation

Indirect inflammatory effect

- Lipid excess activates inflammatory pathways
- Cytokines promote resistance
- β -cell dysfunction may also increase

A single upstream exposure has multiple downstream effects.

Hepatic lipid excess can amplify glucose output



The source also discusses enhanced phosphoenolpyruvate carboxykinase activity.

Adipose tissue functions as an endocrine organ

Stored substrate

Triglyceride mobilization
supplies FFAs.

Hormonal signals


Adipokines regulate
systemic metabolism.

Immune signals

Inflammatory mediators act
on target organs.

Adipose expansion changes signaling, not just energy storage.

Adiponectin ordinarily supports insulin sensitivity



Adiponectin itself ordinarily promotes peripheral insulin sensitivity.

Adipokines have heterogeneous metabolic effects

Insulin-sensitizing example

- Adiponectin decreases blood glucose
- Partly improves insulin responsiveness
- Often reduced with obesity

Other adipose signals

- Some promote hyperglycemia
- Multiple endocrine and cytokine outputs
- Net effects depend on signal balance

Avoid describing all adipokines as either harmful or protective.

Metabolic inflammation is not autoimmunity

Type 2 inflammatory milieu


- Nutrient and lipid excess
- Macrophage/islet cytokine signaling
- Tissue insulin resistance and β -cell stress

Type 1 autoimmune injury

- Loss of immune tolerance
- Islet-reactive lymphocyte mechanisms
- Destructive immune injury to β -cells


The pathogenesis and targets differ despite inflammatory components in both.

Excess nutrients promote cytokine production




This mechanism contributes to both resistance and secretory dysfunction.

Inflammasome activation can increase IL-1 β




IL-1 β is an inflammatory mediator, not a specific diagnostic marker of T2D.

Cytokines extend a local signal systemically




Inflammation constitutes an amplification pathway rather than the only cause.

Lipid excess and inflammation reinforce each other



Conceptual feedback: Resistance can increase lipolysis and sustain lipid excess.

Fatty liver belongs to the metabolic network



MASLD is an associated phenotype; Do not mistake it for a required diagnostic criterion.

Insulin resistance alone does not explain overt T2D

Compensated resistance


- Insulin demand is high
- β -cell secretion increases
- Glucose tolerance can be maintained

Overt type 2 diabetes

- Insulin demand remains high
- β -cell response becomes inadequate
- Chronic hyperglycemia develops


β -cell dysfunction is necessary for the usual progression.

β -cell compensation has finite capacity




This is not a claim that insulin secretion necessarily reaches zero.

Free fatty acids also impair β -cell function



Lipotoxicity can affect insulin action and insulin secretion.

Chronic hyperglycemia can worsen secretion



The source identifies glucotoxicity as a mechanism associated with β-cell dysfunction.

An abnormal incretin effect is implicated

Gut-derived signals

GIP and GLP-1 augment meal-related insulin release.

Disordered incretin axis

Abnormal incretin effects with impaired compensation.

Functional outcome

Less appropriate insulin secretion for a glucose challenge.

Mechanistic overview only; No quantitative hormone-response claim.

Islet amyloid is a characteristic association

Observed in longstanding T2D


- Amyloid accumulates within islets
- Associated with β -cell dysfunction
- Prominent in source discussion

Unresolved direction of causation

- Might contribute to cell failure
- Might reflect preceding β -cell injury
- Association alone does not establish causality

Whether islet amyloid causes or follows β -cell dysfunction remains unresolved.

Genetic variation also influences secretory reserve



β-cell capacity and tissue resistance are jointly consequential.

Multiple β -cell stresses converge

Lipotoxicity

Excess fatty acids

Glucotoxicity

Chronic hyperglycemia

Incretin abnormalities

Less effective meal-linked insulin response

Islet amyloid

Longstanding association; Causality uncertain

Inherited vulnerability modifies this combined stress response.

From visceral obesity to diabetes: A causal synthesis



Schematic assembly from the textbook, not a single obligatory pathway.

Fasting and postprandial glucose reflect different defects

Predominantly fasting elevation

- Insulin fails to suppress liver glucose production
- Continued gluconeogenesis
- Hepatic resistance is a major contributor

Predominantly post-meal elevation

- Insulin-stimulated muscle uptake is impaired
- Less glucose disposal after eating
- Secretory reserve also affects the response

Both patterns can coexist in the same patient.

Phenotypic expression varies across individuals

Mechanism-to-phenotype examples

Central adiposity

Increased FFA flux and insulin resistance

High insulin with normal glucose

Early successful β -cell compensation

Persistent hyperglycemia

Compensation no longer adequate

Steatotic liver

Mechanism-based interpretation, not a clinical diagnostic algorithm.
Parallel manifestation of lipid/metabolic stress

Clinical scenario: Hyperinsulinemia without diabetes

Clinical vignette

An adult with central adiposity has evidence of insulin resistance, increased circulating insulin, but glucose measurements remain within the normal range.

Why can glucose remain normal despite resistance?

β -cell compensation raises insulin secretion sufficiently to meet increased demand—until this adaptive capacity becomes inadequate.

Clinical scenario: Diabetes without marked obesity

Clinical vignette

An adult without obvious generalized obesity develops elevated fasting and postprandial glucose. Imaging or clinical assessment suggests increased central adiposity.

Which misconception should be avoided?

Low apparent overall adiposity does not exclude visceral fat accumulation or insulin resistance; β -cell secretory vulnerability may coexist.

Three common causal misconceptions

“T2D is autoimmune”

No evidence of an autoimmune basis in this source.

“Obesity is sufficient”

Progression also requires inadequate β -cell adaptation.

“Normal BMI excludes risk”

Visceral fat and inherited susceptibility can remain relevant.

Correctly separating risk, mechanism and disease is essential.

Integrated pathogenesis: Four central conclusions

- Polygenic susceptibility changes how adiposity and β -cells respond to metabolic demand.
- Visceral adiposity, inactivity and circadian disruption increase acquired risk.
- Resistance in liver, muscle and adipose tissue generates distinct metabolic consequences.
- Chronic hyperglycemia appears when β -cell secretion no longer compensates adequately.

Primary reading and source boundaries

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. 2026. Chapter 24, The Endocrine System.

Primary topic: “Pathogenesis of Type 2 Diabetes,” p. 1003; subheadings “Genetic Factors” and “Environmental Factors.”

Mechanistic expansion from adjacent section: “Metabolic Defects in Type 2 Diabetes,” pp. 1003–1004.

Conceptual diagrams were newly constructed as editable PowerPoint elements; no original pathology figures were reproduced.